Navigation Links
SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials
Date:5/14/2008

AMSTERDAM, May 14 /PRNewswire/ -- SynCo Bio Partners B.V., a leading GMP biopharmaceutical manufacturer, announced today that it has completed the manufacture and release of ActoGeniX' drug substance AG011 for use in a Phase II clinical trial with ulcerative colitis patients.

ActoGeniX is focused on the development and commercialization of ActoBiotics(TM), a novel class of protein-based biopharmaceuticals that can be orally administered. The Company's lead product AG011 is an ActoBiotic(TM) for treatment of inflammatory bowel disease and has previously been successfully tested in a Phase I clinical trial with Crohn's disease patients.

To provide the AG011 drug product required for the Phase II studies, due to start this summer, SynCo has developed and scaled up the manufacturing process involving cultivation, purification and lyophilisation of AG011. Although the project involved several parties, working virtually simultaneously on different aspects, the GMP batches were produced within the agreed timelines.

Announcing the successful completion of the project, Pierre Warffemius, CEO, said, "Having ActoGeniX choose us to manufacture the GMP batches for their Phase II clinical trials is a clear endorsement of our growing reputation for manufacturing live biopharmaceuticals. The fact that we were able to work on a multi-agency project and deliver the drug substance on time is also an excellent example of project management capabilities."

Mark Vaeck, CEO of ActoGeniX, "The move from Phase I to Phase II clinical trials is a critical step for ActoGeniX so it was imperative that we worked with a GMP-accredited contract manufacturing organisation that had a proven track record in developing processes for biopharmaceuticals, as well as commercial manufacturing capabilities."

ActoGeniX will, in the coming weeks, file the regulatory applications to obtain approval for the start of its AG011 clinical trial during this summer. ActoGeniX
'/>"/>

SOURCE SynCo Bio Partners B.V.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Limited (NASDAQ GS: SEED) (" Origin ", or the " ... China , today announced that the Company will ... 2014, before the market opens on Thursday, January 8, 2015. ... 8, 2015, at 8:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial +1-888-346-8982 in ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... New York, New York (PRWEB) December 13, 2014 ... expansion of its global network and Cold Chain capabilities, ... new Control Tower in Paris, France, to serve Life ... brand new facility equipped with a controlled-ambient warehouse, will ... in-transit storage for vaccines and investigational drugs, patient-clinical specimens, ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... , , STAMFORD, Conn. ... and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced ... Intermezzo ((R)) (zolpidem tartrate sublingual tablet) in the United States. If ... ((R)) has the potential to be the first prescription sleep aid ...
... ... Terrosa Technologies, a provider of Cloud and SaaS ... world wide sales, marketing and distribution responsibilities with Integrated Clinical ... collaboration Clinical Trial Management System (CTMS) tool for the pharmaceutical ...
... time bomb, a deadly mechanism that can be used against ... Universiteit Brussel (VUB) were able to determine the structure and ... for finding ways to set the clock on this internal ... new class of antibiotics. The research was accepted for ...
Cached Biology Technology:Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 2Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 3Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 4Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 5Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 6Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States 7Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Bacteria pack their own demise 2Bacteria pack their own demise 3
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... native flora is in sourcing genetically diverse seed not ... seed. "A common belief is that local native ... projects," says Dr Linda Broadhurst from CSIRO, Australia,s national ... that local seed is adapted to local conditions and ...
... A wild fungus has been found to produce a ... microscopic fungus, known as Gliocladium roseum (NRRL ... rainforest. Gary Strobel of Montana State University ... and that the particular diesel components produced can be ...
... discovered a metabolic deficiency in pancreatic cancer cells that ... deadliest of all cancers. Published in the October ... study results indicate that pancreatic cancer cells cannot produce ... in cell division, immune function and hormone regulation. By ...
Cached Biology News:Obscure fungus produces diesel fuel components 2UC Davis researchers discover Achilles' heel in pancreatic cancer 2UC Davis researchers discover Achilles' heel in pancreatic cancer 3
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Request Info...
Amyloid stain....
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Biology Products: